Abstract
The short-term progression of asymptomatic chronic hepatitis C patients with mild fibrosis isexcellent. Non-invasive test is easy and use to monitor the progression of fibrosis. Interferon regimen isthe treatment for HCV patients, currently direct-acting antiviral drug (DDA) regimens is more effectiveand shorter duration. Many DDA regimens can have sustained viral response (SVR) rates of morethan 90% and safety outcomes. Furthermore, all-oral interferon free regimens are not cost-effectivefor patients with mild fibrosis disease. The HCV treatment should be deferred for a few years and theprogression of fibrosis is regularly monitored. This option is safe until new treatment, which ischeaper, shorter, more effective and more convenient, become available.
 
 Keywords: symptomatic, direct-acting antiviral drug, fibrosis progression, cost
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
